Skip to main content

Table 1 Clinical & Laboratory Characteristics of Patients

From: Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use

ParameterCase 1Case 2Case 3
Age (years)386562
SexFemaleFemaleFemale
IHC lymphoma subtypeGCBGCBNon-GCB
PhenotypesCD5(+), CD10(+), Bcl-2(+), Bcl-6(+), CD20(+), CD3(+), MUM-1(−), CD7(+), CycinD1(−)CD5(+), CD10(−), Bcl-2(+), Bcl-6(+), CD20(+), CD3(+), MUM-1(+), PAX-5(+), CD68(−), CycinD1(−)CD5(+), CD10(−), Bcl-6(+), CD20(+), CD3(−), MUM-1(+), CD56(−), CycinD1(−)
B symptomsYYN
FeverYYN
Night sweatsYNN
Weight lossYNN
Bulky disease (> 7.5 cm)NNN
> 2 extranodal sitesY (terminal ileum, stomach, liver)Y (colon, chest wall)Y (neck region, nasopharynx)
LDH (120–250 U/L)5233245.5267.9
β2-microglobulin (1.0–3.0 mg/L)3.43.391.5
Ki-6770%80%50%
StageIVIVIII
R-IPI prognostic group534
Bone marrow involvementNNN
ComplicationsMalnutrition sinus TachycardiaPulmonary infection
Cholecystitis
Hypertension
T2DM
TreatmentR-CHOPx3(PR) → R-CHOPx1 (PD) → R-Gemoxx2(NR)R-CHOPx4(PR) → R-CHOPx3(SD) → R-Gemoxx4(PR) → R-IMVP16(NR)R-CHOPx3(NR) → DICE (NR) → R-DHAPx2(PD)
  1. LDH Lactate dehydrogenase T2DM: Type 2 diabates
  2. R-CHOP rituximab plus cyclophosphamide, pharmorubicin, vincristine Sulfate (Oncovin), and prednisone
  3. R-Gemox rituximab plus gemcitabine and oxaliplatin
  4. R-IMVP16 rituximab plus ifosfamide, methotrexate, and etoposide
  5. DICE dexamethasone, ifosfamide, cisplatin, and etoposide
  6. R-DHAP rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (platinum)
  7. Case 2 R-IMVP16 regimen was chosen for the patient due to her poor physical state
  8. Case 3 After three courses of R-CHOP, DICE was given to the patient without rituximab because the patient refused to use it